Article
Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia
3 Jul 2017
Abstract excerpt
Interindividual variability in response to 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, with regard to both efficacy and safety is an obvious target for pharmacogenetic research. Many genes have been identified as possible contributors to variability in statin response and safety. Genetic polymorphisms may alter the structure or expression of coded proteins, with potential impacts on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
